Aytu BioPharma, Inc. (AYTU) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AYTU Revenue Growth
Revenue Breakdown (FY 2024)
AYTU's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
AYTU Revenue Analysis (2014–2025)
As of May 8, 2026, Aytu BioPharma, Inc. (AYTU) generated trailing twelve-month (TTM) revenue of $62.6 million, reflecting moderate decline in growth of -6.5% year-over-year. The most recent quarter (Q2 2026) recorded $15.2 million in revenue, up 9.2% sequentially.
Looking at the longer-term picture, AYTU's 5-year compound annual growth rate (CAGR) stands at +19.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $107.4 million in 2023.
Revenue diversification analysis shows AYTU's business is primarily driven by Consumer Health (100%). With over half of revenue concentrated in Consumer Health, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SUPN (+16.3% YoY), TPVG, and ASRT (-5.0% YoY), AYTU has underperformed the peer group in terms of revenue growth. Compare AYTU vs SUPN →
AYTU Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AYTUCurrent | $63M | -6.5% | +19.2% | -11.8% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 TPVG | $97M | - | - | 77.9% | |
 ASRT | $119M | -5.0% | +1.9% | -18.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 COLL | $781M | +19.9% | +20.3% | 24.0% |
AYTU Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $66.4M | +1.8% | $45.8M | 69.0% | $-7,827,000 | -11.8% |
| 2024 | $65.2M | -39.3% | $49.1M | 75.3% | $-1,591,000 | -2.4% |
| 2023 | $107.4M | +11.1% | $66.6M | 62.0% | $-17,065,000 | -15.9% |
| 2022 | $96.7M | +47.3% | $50.3M | 52.0% | $-109,906,000 | -113.7% |
| 2021 | $65.6M | +137.5% | $29.2M | 44.5% | $-58,870,000 | -89.7% |
| 2020 | $27.6M | +277.5% | $19.4M | 70.0% | $-21,131,000 | -76.5% |
| 2019 | $7.3M | +100.0% | $5.1M | 69.9% | $-16,846,637 | -230.1% |
| 2018 | $3.7M | +13.6% | $1.6M | 44.0% | $-19,700,234 | -538.3% |
| 2017 | $3.2M | +25.7% | $1.8M | 56.0% | $-20,125,236 | -624.7% |
| 2016 | $2.6M | +878.8% | $1.6M | 62.6% | $-21,704,397 | -847.0% |
See AYTU's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AYTU Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AYTU vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAYTU — Frequently Asked Questions
Quick answers to the most common questions about buying AYTU stock.
Is AYTU's revenue growth accelerating or slowing?
AYTU revenue declined -6.5% year-over-year, contrasting with the 5-year CAGR of +19.2%. TTM revenue fell to $63M. This reverses the prior growth trend.
What is AYTU's long-term revenue growth rate?
Aytu BioPharma, Inc.'s 5-year revenue CAGR of +19.2% reflects the variable expansion pattern. Current YoY growth of -6.5% is below this long-term average.
How is AYTU's revenue distributed by segment?
AYTU reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.